Relay Therapeutics, Inc. Common StockRLAY
Recorded
Relay Therapeutics, Inc. Common Stock Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration35 min
Key takeaways
- Relay Therapeutics reported a robust first nine months with disclosures in vascular anomalies and breast cancer, and strengthened their balance sheet.
- The company is preparing to become commercial, focusing on regulatory clarity in breast cancer and vascular anomalies.
- They plan regulatory interactions before year-end for their frontline breast cancer phase three trial and accelerated approval path for vascular anomalies.
- Data updates on vascular anomalies will be shared before year-end, with phase one/two triplet data expected in the first half of next year.
- In breast cancer, Zovega showed an 11-month progression-free survival (PFS) in second-line patients, outperforming Capivasertib's 5.5 months post-CDK4/6.
- Phase three enrollment for the Rediscover 2 study is progressing well, with guidance on last patient in expected before year-end.
- Zovega's tolerability profile is favorable, with low grade three hyperglycemia and no stomatitis rash, differentiating it from competitors.
- The first-line breast cancer study will focus on endocrine sensitive patients using Atiramol as the CDK4/6 inhibitor, with regulatory feedback expected before year-end and trial start early next year.
- Phase one/two triplet data will emphasize safety and tolerability as key indicators of durability.
- In vascular anomalies, dose-randomized data showed a 60% response rate, superior to alpelasin's 20-30% response at labeled dose.
- Dose expansion prioritizes 400 mg once daily in patients aged 12 and older, with weight-based dosing ongoing for ages 6 to 11.
- No biological differences are expected between older and younger vascular anomaly patients; early intervention in childhood is preferred.
- Responses deepen over time with symptomatic improvements, including pain reduction.
- Activity is consistent across patient subtypes and PIK3CA mutation status, including patients without documented mutations due to diagnostic limitations.
- Most patients switching from alpelasin or serolimus did so due to intolerance or plateaued response.
- A standard three half-life washout period is required before study entry.
- The vascular anomalies study population is about 70-75% PROS patients and 25-30% lymphatic malformation patients, with no difference in drug performance.
- Relay plans to discuss with FDA a potential accelerated approval pathway pooling PROS and lymphatic malformation patients, seeking clarity on data set size and subgroup requirements.
- The current regulatory endpoint is volumetric response rate with exclusion of 15% and a confidence interval lower bound.
- The vascular anomalies market opportunity in the US is estimated at approximately 15,000 moderate to severe patients, with potential peak sales in the billions at Vijoyce-like pricing.
- Chronic treatment is envisioned, starting early in childhood and continuing lifelong.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring